Virion Therapeutics Reports Broad and Sustained Anti-HBV Immunity Following a Single VRON-0200 Dose in the Majority of Chronically HBV-Infected Patients From its Phase 1b Study at CROI 2026

PHILADELPHIA–(BUSINESS WIRE)–Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies that utilize checkpoint modifiers, today announced at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI), in Denver, CO, that a single intramuscular dose of VRON-0200, its novel, first-in-class, immunotherapy for HBV Functional Cure was able to “spark” and re-awaken durable HBV-specific … [Read more…]

The Cannabist Company Further Extends Forbearance Agreement With Senior Noteholders

CHELMSFORD, Mass.–(BUSINESS WIRE)–The Cannabist Company Holdings Inc. (Cboe CA: CBST) (OTCQB: CBSTF) (“The Cannabist Company” or the “Company”), one of the most experienced cultivators, manufacturers, and retailers of cannabis products in the United States, today announced that the ad hoc group of noteholders of the Company’s 9.25% Senior Secured Notes due December 31, 2028 and … [Read more…]

NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, March 3, 2026. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. … [Read more…]

Science Corp. and Neurosoft Bioelectronics Announce Novel BCI Ecosystem Partnership

Deal Joins Science’s World-Class BCI Tools with Neurosoft’s Leading Neural Data Platform ALAMEDA, Calif. & GENEVA–(BUSINESS WIRE)–Science Corporation, the pioneering full-stack neural engineering company focused on restoring and extending life, and Neurosoft Bioelectronics, a neural data company utilizing ultra-soft interfaces to achieve full-cortical coverage powering a foundation AI model of the brain, have partnered to … [Read more…]

Goli Nutrition Launches the “Oscars for Creators” with Inaugural Black-Tie Gala

600 creators will walk the red carpet as social commerce surpasses $100 billion WEST HOLLYWOOD, Calif.–(BUSINESS WIRE)–#ExpoWest–Goli Nutrition Inc., in collaboration with TikTok, will host the inaugural Goli Gala on March 3 in Anaheim, California. The awards ceremony will occur on the opening night of Natural Products Expo West, the largest natural and organic products … [Read more…]

Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026

BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Monday, March 2, 2026, at 4:30 p.m. E.T., to discuss its fourth quarter and full year 2025 financial results. Quanterix will issue a press release regarding its … [Read more…]

Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference

HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to present at the upcoming 46th Annual TD Cowen Healthcare Conference in Boston. Pulse Biosciences’ Management is scheduled to present on Wednesday, March 4, 2026, at 1:10 pm … [Read more…]

FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia

– First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment – – Approval expands Genentech’s fixed-duration portfolio by providing eligible first-line patients another option alongside the established Venclexta plus Gazyva regimen – SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, … [Read more…]

Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D

TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo Company, Limited (TSE: 4568) has appointed John Tsai, MD to succeed Ken Takeshita, MD, who is stepping down as Global Head of R&D, effective April 1, 2026. Dr. Tsai will bring more than 25 years of proven leadership and experience driving innovation to further grow the rich Daiichi … [Read more…]

Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026

NEW YORK–(BUSINESS WIRE)–Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast at 4:30 p.m. EST on Thursday, February 26, 2026 to report financial results … [Read more…]